13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001958125
Total reported value
$532.1M
$532.1M
40 檔
33.5%
The Q2 2025 SEC filing reveals that Catalio Capital Management, LP held a total portfolio value of $532.1M, covering 40 public equity positions.
During Q2 2025, Catalio Capital Management, LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly & Co | Stock-Healthcare | 8.81% | — | +127.67% | |
| 2 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 8.40% | -0.33% | -3.65% | |
| 3 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 7.20% | -4.04% | EXIT | |
| 4 | ASND | Ascendis Pharma A/S | Stock-Other | 6.51% | -6.17% | EXIT | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 6.46% | — | +55.28% | |
| 6 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 6.41% | -0.30% | -10.25% | |
| 7 | GILD | Gilead Sciences Inc | Stock-Healthcare | 5.27% | +1.62% | — | |
| 8 | BSX | Boston Scientific CORP | Stock-Healthcare | 5.16% | -3.92% | EXIT | |
| 9 | CYTK | Cytokinetics Inc | Stock-Healthcare | 4.17% | -2.97% | EXIT | |
| 10 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 4.13% | -0.10% | +21.39% | |
| 11 | TEVA | Teva Pharmaceutical-sp Adr | Stock-Healthcare | 4.11% | — | — | |
| 12 | CORT | Corcept Therapeutics Inc | Stock-Healthcare | 3.68% | — | — | |
| 13 | NTRA | Natera Inc | Stock-Healthcare | 3.45% | +1.23% | — | |
| 14 | ADPT | Adaptive Biotechnologies | Stock-Other | 3.41% | -2.10% | EXIT | |
| 15 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.92% | -9.22% | -2.22% | |
| 16 | GPCR | Structure Therapeutics Inc | Stock-Other | 2.92% | +0.22% | -4.86% | |
| 17 | ADMA | Adma Biologics Inc | Stock-Healthcare | 2.18% | — | — | |
| 18 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 2.09% | — | — | |
| 19 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 1.63% | -1.74% | — | |
| 20 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 1.61% | — | +41.86% | |
| 21 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 1.35% | -0.57% | EXIT | |
| 22 | QURE | uniQure N.V. | Stock-Other | 1.22% | -1.68% | EXIT | |
| 23 | WGS | Genedx Holdings CORP | Stock-Other | 1.19% | — | — | |
| 24 | TARA | Protara Therapeutic Inc | Stock-Other | 1.03% | -0.26% | +49.39% | |
| 25 | OM | Outset Medical Inc | Stock-Other | 0.67% | +0.01% | — | |
| 26 | SEPN | Septerna Inc | Stock-Other | 0.65% | +1.89% | -71.26% | |
| 27 | REPL | Replimune Group Inc | Stock-Other | 0.64% | — | -7.11% | |
| 28 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.44% | — | -27.05% | |
| 29 | VIR | Vir Biotechnology Inc | Stock-Other | 0.41% | — | -36.51% | |
| 30 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 0.38% | — | — | |
| 31 | IRON | Disc Medicine Inc | Stock-Other | 0.34% | +0.55% | — | |
| 32 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.27% | — | -6.84% | |
| 33 | BCAX | Bicara Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 34 | MGX | Metagenomi Therapeutics Inc | Stock-Other | 0.16% | -0.03% | — | |
| 35 | KPTI | Karyopharm Therapeutics Inc | Stock-Other | 0.13% | +0.69% | -6.17% | |
| 36 | HYPR | Hyperfine Inc | Stock-Other | 0.11% | +0.03% | — | |
| 37 | ✓ | Mersana Therapeutics Inc | Stock-Other | 0.10% | — | -8.07% | |
| 38 | ATAI | AtaiBeckley Inc. | Stock-Other | 0.09% | — | — | |
| 39 | GUTS | Fractyl Health Inc | Stock-Other | 0.07% | +0.39% | — | |
| 40 | FTH | Faeth Therapeutics Inc | Stock-Other | 0.03% | -0.03% | — |
According to official SEC Form 13F filings, Catalio Capital Management, LP reported a total U.S. public equity portfolio value of $532.1M across 40 disclosed positions in Q2 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including LLY, BBIO, SLNOEUR) accounted for 33.5% of total reported equity market value during Q2 2025.
During Q2 2025, Catalio Capital Management, LP's top holdings by market value included LLY (8.8%)、BBIO (8.4%)、SLNOEUR (7.2%). The largest single position, LLY, represented 8.8% of total portfolio value.
In Q2 2025, Catalio Capital Management, LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.